慢性丙型肝炎患者感染病毒基因型对抗病毒治疗应答的影响

doi:10.3969/j.issn.1672-5069.2014.02.020

Abstract

Xiao Zuohan, Meng Gang, Wang Lizhi.. Influence of genotypes to sustained viral response in patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 188-189.

[1] 中华医学会. 丙型肝炎防治指南. 中华传染病杂志，2004，22（2）：131-136.
[2] 康富标，赵敏.丙型肝炎抗病毒治疗研究进展.中华肝脏病杂志，2006，（12）：933-935.
[3] Ghany MG，Strader DB，Thomas DL，et al. Diagnosis，management and treatment of hepatitis C:all update. Hepatology，2009，49（4）:1335-1374.
[4] McCanghan GW，Omata M，Amarapurkar D，et al. Asian-pacific association for the stady of the liver consensus:Statements on the diagnosis，management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol， 2007，22（5）:615-633.
[5] 姜雪强，邹小静，田德英. 聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者的病毒学应答.临床肝胆病杂志，2011，27（4）：417-419.
[6] 李发武，王文琦，吴福全，等. 不同聚乙二醇化干扰素治疗丙型肝炎病毒感染临床观察. 实用肝脏病杂志，2010，13（3）：185-187.
[7] 王自林，宣艳，王丽莉.丙型肝炎病毒基因型与抗病毒治疗.实用肝脏病杂志，2010，13（2）：154-157.
[8] 周友乾，尹凤鸣，冯经华.丙型肝炎病毒载量与基因型和抗病毒疗效的关系研究.实用肝脏病杂志，2011，14（5）：340-343.
[9] 朱义玲，陈丽，赵卫峰，等. 聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察. 实用肝脏病杂志，2012，15（2）：123-125.
[10] 肖非，马科，黄加权.基因I型慢性丙型肝炎初治患者获得持续病毒学应答的相关因素研究.实用肝脏病杂志，2011，14（6）：420-421，426.
[11] 潘剑，俞海英，丁巧云，等. 慢性丙型肝炎患者HCV基因型分析. 实用肝脏病杂志，2012，15（5）：390-391.
[12] David LT，Chloe LT，Mavreen PM，et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature，2010，461:798-802.
[13] Honda M，Sakai A，Yamashita T，et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C.Gastroenterology，2010，139（2）:499-509.
[14] 周友乾，尹凤鸣，冯经华. 慢性丙型肝炎患者年龄和感染方式对抗病毒治疗应答的影响.实用肝脏病杂志，2012,15（5）：387-389.
[15] 冯婥，杜宇，黄远明,等.慢性丙型肝炎不同抗病毒药物治疗的临床观察分析. 中西医结合肝病杂志，2008,15（4）：200-202.
[16] 池肇春. 慢性丙型肝炎治疗现状与进展. 中西医结合肝病杂志，2012,16（2）：65-70.

Influence of genotypes to sustained viral response in patients with chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[4]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[5]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[6]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[7]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[8]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[9]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[10]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[11]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[12]	Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.
[13]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.
[14]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.
[15]	Jiang Hongda, Zhou Haizhou.. Serum autoantibodies in patients with hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 817-820.